Piermont Valley Acquisition Corp 8-K

What Happened

• Piermont Valley Acquisition Corp (CMCAF) entered into a definitive Agreement and Plan of Merger with Tigerless Health, Inc. on April 17, 2026; the company disclosed the agreement in an 8-K filed April 20, 2026. The deal is a two-step reorganization: Tigerless will merge into a Tigerless subsidiary, then a second Tigerless subsidiary will merge into Piermont, resulting in a new public operating company (Pubco) — Tigerless AI Holdings Inc. — with Tigerless and Piermont as wholly-owned subsidiaries. The parties expect to close in the second half of 2026, subject to Piermont and Tigerless shareholder approvals, SEC registration effectiveness and Nasdaq listing.

Key Details

• Share conversion and ownership: upon closing Tigerless stockholders are expected to receive 5,600,000 shares of Pubco Class A and 22,400,000 shares of Pubco Class B; Piermont stockholders are expected to receive 5,952,886 shares of Pubco Class A (assumes no redemptions). Pubco Class A generally has no voting rights; Class B has one vote per share and is convertible into Class A.
• Earnout: up to $100.0 million in contingent post‑closing consideration payable in Pubco Class A shares across four annual earn‑out periods (max $25.0M per year). Earnouts pay out if one of three tests is met (e.g., >30% year‑over‑year revenue or policyholder growth; >3% gross margin improvement; or ≥60% systems integration plus measurable efficiency gains). Earnout share counts use a 10‑day VWAP at each measurement date.
• Financing, approvals and timing: parties will seek to list Pubco Class A on Nasdaq and to secure a PIPE financing of at least $5.0 million (no PIPE commitments in place). Closing is conditioned on customary items: shareholder approval(s), Registration Statement effectiveness, no blocking regulatory orders, and other contract conditions. The agreement can be terminated if the deal is not closed by Sept 30, 2026 (extendable to Dec 31, 2026 in certain SEC circumstances).
• Governance and lockups: certain Piermont insiders and Tigerless shareholders will enter lockup and support agreements to vote in favor of the transaction, waive appraisal/dissenters’ rights, and not redeem Piermont shares for the trust account.

Why It Matters

• The transaction would convert Piermont from a SPAC shell into an operating public company that combines Piermont and Tigerless under Pubco, with Tigerless founders/holders retaining substantial voting control via Pubco Class B shares. For Piermont investors, key implications include potential dilution from the earnout (up to $100M) and any PIPE, the impact of insider lockups/support agreements, and the deal’s dependence on shareholder votes, SEC clearance and Nasdaq approval — any of which could delay or block the closing.